Want to see IN:MEDICAMEQ full AI Analyst Report?
Total Valuation
Medicamen Biotech Limited has a market cap or net worth of ₹4.39B. The enterprise value is ₹3.02K.
Market Cap₹4.39B
Enterprise Value₹3.02K
Share Statistics
Medicamen Biotech Limited has 13,562,815 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,562,815
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Medicamen Biotech Limited’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.10%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)3.10%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee4.88M
Profits Per Employee238.06K
Employee Count405
Asset Turnover0.53
Inventory Turnover2.05
Valuation Ratios
The current PE Ratio of Medicamen Biotech Limited is 40.3. Medicamen Biotech Limited’s PEG ratio is 1.06.
PE Ratio40.3
PS Ratio1.51
PB Ratio1.08
Price to Fair Value1.08
Price to FCF-7.51
Price to Operating Cash Flow-35.00
PEG Ratio1.06
Income Statement
In the last 12 months, Medicamen Biotech Limited had revenue of 1.98B and earned 96.41M in profits. Earnings per share was 7.22.
Revenue1.98B
Gross Profit540.86M
Operating Income123.69M
Pretax Income119.84M
Net Income96.41M
EBITDA227.00M
Earnings Per Share (EPS)7.22
Cash Flow
In the last 12 months, operating cash flow was -124.06M and capital expenditures -21.75M, giving a free cash flow of -145.81M billion.
Operating Cash Flow-124.06M
Free Cash Flow-145.81M
Free Cash Flow per Share-10.75
Dividends & Yields
Medicamen Biotech Limited pays an annual dividend of ₹1, resulting in a dividend yield of 0.31%
Dividend Per Share₹1
Dividend Yield0.31%
Payout Ratio12.21%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change-4.97%
50-Day Moving Average248.47
200-Day Moving Average292.85
Relative Strength Index (RSI)76.02
Average Volume (3m)4.03K
Important Dates
Medicamen Biotech Limited upcoming earnings date is Nov 6, 2026, TBA (Confirmed).
Last Earnings DateAug 14, 2026
Next Earnings DateNov 6, 2026
Ex-Dividend Date―
Financial Position
Medicamen Biotech Limited as a current ratio of 2.54, with Debt / Equity ratio of 0.00%
Current Ratio2.54
Quick Ratio1.75
Debt to Market Cap0.16
Net Debt to EBITDA0.73
Interest Coverage Ratio3.54
Taxes
In the past 12 months, Medicamen Biotech Limited has paid 21.88M in taxes.
Income Tax21.88M
Effective Tax Rate0.18
Enterprise Valuation
Medicamen Biotech Limited EV to EBITDA ratio is 13.86, with an EV/FCF ratio of -7.93.
EV to Sales1.59
EV to EBITDA13.86
EV to Free Cash Flow-7.93
EV to Operating Cash Flow-9.01
Balance Sheet
Medicamen Biotech Limited has ₹312.64M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹312.64M billion.
Cash & Marketable Securities₹312.64M
Total Debt₹0.00
Net Cash₹312.64M
Net Cash Per Share₹23.05
Tangible Book Value Per Share₹205.91
Margins
Gross margin is 29.28%, with operating margin of 6.25%, and net profit margin of 4.88%.
Gross Margin29.28%
Operating Margin6.25%
Pretax Margin6.06%
Net Profit Margin4.88%
EBITDA Margin11.48%
EBIT Margin7.83%
Analyst Forecast
The average price target for Medicamen Biotech Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast24.66%
EPS Growth Forecast10.89%